Literature DB >> 15652854

Ultrastructure of internal limiting membrane in myopic foveoschisis.

Hajime Bando1, Yasushi Ikuno, Jun-Sub Choi, Yasuo Tano, Ichiro Yamanaka, Tatsuro Ishibashi.   

Abstract

PURPOSE: To reveal the pathogenesis of myopic foveoschisis (MF).
DESIGN: Clinicopathological report.
METHODS: Internal limiting membranes (ILMs) were collected from ten patients with MF and five patients with idiopathic macular hole (IMH) as a control. Samples were subjected to transmission electron microscopic study. Characteristics of the ILM were compared between the two groups.
RESULTS: Collagen fiber and cell debris were identified on the inner surface of ILM in seven eyes (70%) with MF, significantly more (P < .05) than found in IMH subjects (0%). More fibrous glial cells were likely to be found on the inner surface of ILM. No significant difference in fibroblast-like cell adhesion was observed.
CONCLUSIONS: Collagen fiber and cellular component are suggested to play an important role in developing MF. ILM peeling may be essential for vitrectomy for MF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15652854     DOI: 10.1016/j.ajo.2004.07.027

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  23 in total

1.  Vitrectomy and gas tamponade without internal limiting membrane peeling for myopic foveoschisis.

Authors:  A K H Kwok; T Y Y Lai; W W K Yip
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

2.  Macular cysts, holes and cavitations : 2006 Jules Gonin lecture of the Retina Research Foundation.

Authors:  A Gaudric
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-30       Impact factor: 3.117

3.  Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization.

Authors:  Noriaki Shimada; Kyoko Ohno-Matsui; Kengo Hayashi; Takeshi Yoshida; Takashi Tokoro; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2011-05-27       Impact factor: 2.447

4.  Morphologic and functional outcomes of different optical coherence tomography patterns of myopic foveoschisis after vitrectomy and inner limiting membrane peeling.

Authors:  Giancarlo Sborgia; Francesco Boscia; Alfredo Niro; Ermete Giancipoli; Giuseppe D'Amico Ricci; Alessandra Sborgia; Luigi Sborgia; Nicola Recchimurzo; Mario R Romano; Giuseppe Addabbo; Giovanni Alessio
Journal:  Eye (Lond)       Date:  2019-06-17       Impact factor: 3.775

Review 5.  Myopic foveoschisis: a clinical review.

Authors:  R Gohil; S Sivaprasad; L T Han; R Mathew; G Kiousis; Y Yang
Journal:  Eye (Lond)       Date:  2015-03-06       Impact factor: 3.775

6.  Ultrastructural analyses of internal limiting membrane excised from highly myopic eyes with myopic traction maculopathy.

Authors:  Reiji Yokota; Akito Hirakata; Nobutsugu Hayashi; Kazunari Hirota; Tosho Rii; Yuji Itoh; Tadashi Orihara; Makoto Inoue
Journal:  Jpn J Ophthalmol       Date:  2017-10-25       Impact factor: 2.447

7.  Diagnosis and treatment of myopic traction maculopathy.

Authors:  Ping-Bo Ouyang; Xuan-Chu Duan; Xiao-Hua Zhu
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

8.  Pathology of macular foveoschisis associated with degenerative myopia.

Authors:  Johnny Tang; Michael B Rivers; Andrew A Moshfeghi; Harry W Flynn; Chi-Chao Chan
Journal:  J Ophthalmol       Date:  2010-08-12       Impact factor: 1.909

9.  Foveal regeneration after resolution of cystoid macular edema without and with internal limiting membrane detachment: presumed role of glial cells for foveal structure stabilization.

Authors:  Andreas Bringmann; Martin Karol; Jan Darius Unterlauft; Thomas Barth; Renate Wiedemann; Leon Kohen; Matus Rehak; Peter Wiedemann
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

10.  Foveal anatomical status and surgical results in vitrectomy for myopic foveoschisis.

Authors:  Yasushi Ikuno; Kaori Sayanagi; Kaori Soga; Yusuke Oshima; Masahito Ohji; Yasuo Tano
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.